FDA – Page 65 – Policy & Medicine

Milwaukee Journal Sentinel: The Case of BMP-2 Ignoring Any Benefit from Innovation

FDA Proposes Changes to Medical Device 510K Program

FDA and Disease Awareness Programs

FDA Opioid REMS: ACPE Outlines Pharmacists Role in Education

FDA: Warning Letters May Double in 2010

FDA Opioid REMS Advisory Panel Focus on CME for Improving Practice

FDA Pain REMS Advisory Committee to Include Presentations on Continuing Education in the Health Professions as a Tool for Implementation

Top Three Diabetes Organizations Issue Physician Guidance on Avandia and CV Risk

FDA REMS: Continuing Medical Education Requirement for Malaria Drug

FDA Avandia Hearing Update – Committee Votes Increased Risk of CV events, No Increase in Mortality